TLR4 and ovarian carcinoma: On the other hand, IFN-γ enhances the anti-tumor immune response by activating cytotoxicity in immune cells such as NK and CD8+ T cells, and combining IFNs with modalities such as immunotherapy or TLR4 agonists show promise in reversing immunosuppression and boosting cytotoxicity against ovarian cancer cells, offering effective therapeutic approaches for combating the disease [20].